Panbela Therapeutics

Panbela Therapeutics, Inc. is a biopharmaceutical company in the advanced stage of clinical development, dedicated to creating innovative treatments for pressing medical necessities. The company's primary focus is on addressing the needs of individuals suffering from pancreatic cancer. With SBP-101 as its primary candidate, a metabolic inhibitor targeting polyamine, the company aims to revolutionize the treatment of metastatic pancreatic ductal adenocarcinoma.